Loss Expression of Uroplakin III is Associated with Clinicopathologic Features of Aggressive Bladder Cancer

Urology

Volumn 72, Issue 2, 2008, Pages 444-449

  Matsumoto, Kazumasa ^a   Satoh, Takefumi ^a   Irie, Akira ^b   Ishii, Junichiro ^b   Kuwao, Sadahito ^c   Iwamura, Masatsugu ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c Higashiyamato Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; UROPLAKIN; UROPLAKIN III; VIRUS VECTOR;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL FEATURE; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; STATISTICAL SIGNIFICANCE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMANS; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 48349083444     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.128     Document Type: Article

References (20)

1. Wu X.R., Lin J.H., Walz T., et al. Mammalian uroplakins: a group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 269 (1994) 13716-13724
2. Yu J., Lin J.H., Wu X.R., et al. Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins. J Cell Biol 125 (1994) 171-182
3. Lu J.J., Kakehi Y., Takahashi T., et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res 6 (2000) 3166-3171
4. Olsburgh J., Harnden P., Weeks R., et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199 (2003) 41-49
5. Kurahashi T., Hara I., Oka N., et al. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 11 (2005) 3773-3777
6. Wu X., Kakehi Y., Zeng Y., et al. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol 174 (2005) 2138-2143
7. Xu X., Sun T.T., Gupta P.K., et al. Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer 93 (2001) 216-221
8. Zhang J., Ramesh N., Chen Y., et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res 62 (2002) 3743-3750
9. Zhu H.J., Zhang Z.Q., Zeng X.F., et al. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer. Cancer Gene Ther 11 (2004) 263-272
10. Varga A.E., Leonardos L., Jackson P., et al. Methylation of a CpG island within the uroplakin Ib promoter: a possible mechanism for loss of uroplakin Ib expression in bladder carcinoma. Neoplasia 6 (2004) 128-135
11. Cowled P., Kanter I., Leonardos L., et al. Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation. Neoplasia 7 (2005) 1091-1103
12. Moll R., Wu X.R., Lin J.H., et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 147 (1995) 1383-1397
13. Kaufmann O., Volmerig J., and Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 113 (2000) 683-687
14. Sesterhenn I.A. Tumours of the urinary systems, in, WHO Classification Tumours of the Urinary System and Male Genital Organs (2004), IARC Press, Lyon 89-157
15. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51 (2007) 152-160
16. Matsumoto K., Shariat S.F., Ayala G.E., et al. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 66 (2005) 441-446
17. Matsumoto K., Irie A., Satoh T., et al. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 70 (2007) 602-607
18. Hara S., Miyake H., Fujisawa M., et al. Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. Jpn J Clin Oncol 31 (2001) 399-402
19. Leissner J., Koeppen C., and Wolf H.K. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 169 (2003) 955-960
20. Lotan Y., Gupta A., Shariat S.F., et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23 (2005) 6533-6539